Original Source(s)
Related Content
FDA Approves Gedatolisib in Breast Cancer
In VIKTORIA-1, gedatolisib-containing regimens resulted in longer median progression-free survival than fulvestrant alone.
July 14, 2026
-
2 min
Chemoimmunotherapy Linked to HNSCC Response
Higher pathologic response rates with chemoimmunotherapy versus immunotherapy alone call for phase 3 trials, but survival implications remain unknown.
June 5, 2026
-
6 min
Poor Diet Quality Linked to Oral Cancer
Large prospective cohort data showed stronger associations among women without substantial tobacco or alcohol exposure.
June 5, 2026
-
3 min